(October 1, 2015) A new study published in the Journal of Clinical Oncology shows that women with the most common type of ovarian cancer can safely take hormone replacement therapy (HRT), and it could have a beneficial effect on their survival. The 24-year, phase III international trial provides the strongest evidence yet that women with epithelial ovarian cancer — which accounts for 80-90 per cent of cases — can safely take HRT during or after their treatment.
Related Topics
OCRA Sponsors NCCN 2025 Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in October 2025 to reflect NCCN’s release of the 2025 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2025 Patient Guidelines for Cervical, Ovarian, and Uterine Cancer. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful guides for anyone newly diagnosed to help … Continued
KVIA-TV ABC-7 Features OCRA-Funded Research Developing Nanotechnology for Ovarian Cancer Detection
KVIA-TV ABC-7 News El Paso recently spotlighted the groundbreaking work of OCRA-funded researcher Daniel Heller, PhD of Memorial Sloan Kettering Cancer Center, whose research lab is working to develop a liquid biopsy that uses nanotechnology and artificial intelligence (AI) to detect ovarian cancer earlier. We’re developing a liquid biopsy that uses nano sensors and AI … Continued
Researchers Discover Potential Therapeutic Targets for Low-Grade Serous Ovarian Cancer
Scientists have identified sixteen potential therapeutic targets in low-grade serous ovarian cancer by studying proteins at the molecular level, with results published on August 11, 2025, in the journal Cancer Cell. The research was led by Ernst Lengyel, MD, PhD of University of Chicago, along with Matthias Mann, PhD, of the Max Planck Institute of … Continued